Pre-Made Briobacept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Briobacept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Briobacept, consisting of an extracellular domain of B cell activating factor-receptor (BAFF-R/BLyS receptor) fused to human IgG-Fc. Briobacept, target B cell surface receptors and soluble mediators respectively, which is useful for the Systemic Lupus Erythematosus therapies
| Products Name (INN Index) | Pre-Made Briobacept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF |
|---|---|
| INN Name | briobacept |
| Target | TNFSF13B |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Biogen,?Inc. (Cambridge MA USA) / Genentech Inc. (S. San Francisco CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFSF13B |
| Package |
